Merck’s Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
Go back to Merck’s Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC)| Merck & Co. (NYSE: MRK) | Delayed: 129.56 +4.19 (3.34%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $125.37 | 52 Week High | $65.46 | |||
| Open | $126.18 | 52 Week Low | $47.97 | |||
| Day High | $129.61 | P/E | 88.14 | |||
| Day Low | $125.99 | EPS | $1.47 | |||
| Volume | 7,833,992 | |||||
